Phenotypes of Patients with Direct Oral Anticoagulant (DOAC) Underdosing in Atrial Fibrillation: Results from the ARENA Registry

C Brockmüller, AD Meid, J Senges, M Hochadel… - Clinical Drug …, 2024 - Springer
Methods The prospective ARENA registry is a multi-centre study on patients with atrial
fibrillation in Germany. Patients gave detailed information on medication, including over-the …

Direct-Acting Oral Anticoagulants and Potential Inconsistencies with FDA-Approved Dosing for Non-Valvular Atrial Fibrillation: A Retrospective Real-World Analysis …

B DeLor, JJ Glover, TJ Hartman, LL Manzey… - Journal of general …, 2024 - Springer
Background Direct-acting oral anticoagulants (DOACs) are recommended to reduce risk of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) …

Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk

J An, TC Cheetham, T Luong, DT Lang, MS Lee… - Clinical Therapeutics, 2023 - Elsevier
Purpose The effectiveness and tolerability of a reduced dose (110 mg) of dabigatran versus
the standard dose (150 mg) were evaluated in subgroups of patients with atrial fibrillation …

Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States

A Sandhu, LA Kaltenbach, K Chiswell… - … Quality and Outcomes, 2023 - Am Heart Assoc
BACKGROUND: Among patients hospitalized for atrial fibrillation, the frequency of off-label
direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and …

Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation

A Sandhu, LA Kaltenbach, K Chiswell, V Shimoga… - medRxiv, 2023 - medrxiv.org
Introduction Among patients hospitalized for atrial fibrillation (AF), the frequency of off-label
direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and …

Effectiveness and Safety of Dabigatran 110 Mg Versus 150 Mg for High Bleeding Risk Patients with Atrial Fibrillation

J An, TC Cheetham, T Luong, DT Lang, MS Lee… - Available at SSRN … - papers.ssrn.com
Background: We evaluated the effectiveness and safety of reduced dose of dabigatran (110
mg) versus standard dose (150 mg) in high bleeding risk subgroups with AF. Methods: We …